Drug innovation and product pipelines in the cardiometabolic field lag due to the inherent time and cost of evidence generation required for regulatory evaluation and approval.
Several factors can affect delivery success, drive up costs, and potentially delay time to market. They include:
- longer trial period
- Intensive Testing Related to Trials
- poor medication compliance
- Delay detection of critical signals related to endpoint capture
- Underrepresented patient population for intended treatment
Medable Products in the field of cardiometabolism offer a best-in-class digital portfolio designed to provide innovative integrated digital solutions around clinical workflows and established points of care between patients and their clinicians. They map and describe patients’ journeys through healthcare and where and how they interact with clinical research teams.
The company’s products are designed to improve the patient experience, enhance clinical care and drive more scientific data generation and timely endpoints for target indications to accelerate research.
on a scheduled webinar June 9th at 1pm ET, Medable will highlight how it addresses drug development challenges and improves patient experience in the context of clinical research. Best-in-class digital products in digital products for cardiometabolism.
Webinar panelists include:
Claire Marsden, PhD, Vice President, DCT Solutions, Cardiovascular and Metabolic Diseases, Medable
Claire has worked in the biopharmaceutical and CRO industry for over 25 years in all phases of clinical development, including positions at major pharmaceutical companies such as GSK, Pfizer, Novartis and Bayer, as well as biotech companies Alnylam and Lexicon. She has also worked for CROs such as IQVIA and its predecessors Quintiles and Covance/LabCorp.
During her tenure at Medable, Claire worked with clients and internal teams to develop DCT solutions designed around the patient to optimize inclusivity and operational efficiency to transform drug development and registration.
MaryAnne Rizk, PhD, Chief Strategy Officer, Medable
Rizk joins Medable as Chief Strategy Officer after two years leading the digital R&D cloud strategy at IQVIA. Prior to that, Rizk was Oracle’s Global Vice President of CRO Partnerships for five years, and previously served as a Director of Medidata Solutions and a Program Manager at Merck. In August, Rizk was named a PharmaVoice 100 Leader.she
She is also a member of the Association of Women Entrepreneurs in Healthcare, the Prix Galien Foundation Digital Advisory Board, and the Society of Clinical Research Sites (SCRS) Innovation Committee.
Tammy D’Lugin-Monroe, Vice President, Global Therapeutic Strategy Innovation, Syneos Health
Before joining Syneos Health, D’Lugin-Monroe held various positions at CRO PPD and subsidiary Acurian, where she served as Executive Director, customizing strategic enrollment solutions and effective operational delivery across PPD businesses. She also served as Global Senior Program Director for Cardiovascular and Metabolic Diseases.
photo: Warchi, Getty Images
